Related Experiment Video

Updated: Jun 23, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening

Róbert Kiss1, Tímea Polgár, Annet Kirabo

  • 1Department of Pharmaceutical Chemistry, Semmelweis University, 9 Hogyes Endre u., Budapest H-1092, Hungary.

Bioorganic & Medicinal Chemistry Letters
|May 19, 2009
PubMed

Insights

Novel Janus kinase 2 (JAK2) inhibitors were identified using structure-based virtual screening. One potent and specific inhibitor, G6, shows promise for treating myeloproliferative disorders and hematologic malignancies driven by JAK2 activity.

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Janus kinase 2 (JAK2) is implicated in myeloproliferative disorders and hematologic malignancies.
  • A specific JAK2 mutation (Val617Phe) is prevalent in polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
  • Targeting JAK2 kinase activity presents a significant therapeutic opportunity.

Purpose of the Study:

  • To identify novel JAK2 inhibitors through structure-based virtual screening.
  • To evaluate the potency and specificity of identified inhibitors.
  • To find potential lead candidates for treating JAK2-related hematologic conditions.

Main Methods:

  • Structure-based virtual screening was employed to identify potential JAK2 inhibitors.
  • Inhibitor candidates were assessed for potency and specificity against JAK2.
  • Lead compounds were selected based on their efficacy and selectivity profiles.

Main Results:

  • The virtual screen successfully identified novel JAK2 inhibitors.
  • Compound G6 demonstrated significant potency and specificity for JAK2.
  • G6 emerged as a promising lead candidate for further therapeutic development.

Conclusions:

  • JAK2 kinase inhibitors hold therapeutic potential for myeloproliferative disorders and hematologic malignancies.
  • Structure-based virtual screening is an effective method for discovering novel kinase inhibitors.
  • Compound G6 represents a potential therapeutic agent for diseases associated with elevated JAK2 activity.

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Concept Videos

Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...